Please login to the form below

Not currently logged in
Email:
Password:

Paul Blake joins Oxford BioMedica

He will lead the development of pipeline of gene and cell therapies
paul blake oxford biomedica

Oxford BioMedica has named Dr Paul Blake as chief development officer.

Dr Blake, who is already a board member at the UK-based gene therapy specialist, will assume his new role on September 1. He will head the clinical development of the company's pipeline of gene and cell therapies.

Prior to taking the position at Oxford BioMedicia Dr Blake was senior VP and chief medical officer of Canada-based biopharma AEterna Zentaris- a position he held from 2006 to 2014.

His career includes senior managed roles at Cephalon and a senior VP position at SmithKline Beecham Pharmaceuticals, now GSK.

John Dawson, CEO of Oxford BioMedica, said: “His insight and guidance as a Non-Executive Board member have been invaluable and his extensive experience in the strategic clinical development of innovative therapies will be important to Oxford BioMedica as we continue to develop our broad pipeline of novel gene and cell therapies.”

27th August 2014

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
Six ways to improve diversity in clinical trials
Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...